血管局限型肾AL淀粉样变的流行病学与临床病理特征
本研究通过法国巴黎医院数据库回顾性分析35例肾活检证实的血管局限型肾AL淀粉样变患者,该表型约占肾AL淀粉样变的9%。患者诊断时eGFR显著降低、蛋白尿程度较轻,心脏受累比例高,达到深度血液学缓解者总生存期显著更长。
要点
- 血管局限型肾AL淀粉样变约占肾AL淀粉样变的9%,可能被低估。
- 诊断时中位尿蛋白/肌酐比仅0.5 g/g,但eGFR中位36.2 mL/min/1.73 m2。
核心结论
- 血管局限型肾AL淀粉样变可能诊断不足,表现为eGFR显著降低、低级别蛋白尿和总体预后严重。
- 快速达到深度血液学缓解是保护长期肾脏和患者结局的关键。
研究设计与样本
- 回顾性研究,通过挖掘法国巴黎医院数据库纳入35例肾活检证实的血管局限型肾AL淀粉样变患者。
- 该表型约占肾AL淀粉样变病例的9%。
主要发现
- 所有患者肾活检显示 predominantly 或仅(n=21)肾内血管沉积,63%为lambda同种型。
- 诊断时中位尿蛋白/肌酐比为0.5 g/g,血清肌酐181(133-216)µmol/L,eGFR 36.2(24.3-49.6)mL/min/1.73 m2。
- 67%的患者存在心脏受累。
- 除1例外所有患者检出血清和/或尿单克隆丙种球蛋白病,31例(88%)游离轻链比值异常。
- 28例接受治疗的患者中,血液学和肾脏缓解率分别为75%(其中深度血液学缓解43%)和18%。
临床怎么用
- 对肾AL淀粉样变患者应警惕血管局限型表型,即使蛋白尿程度较轻也需评估肾功能。
- 治疗应致力于快速达到深度血液学缓解以改善长期肾脏和患者生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kidney involvement, along with cardiac disease, is the most frequent manifestation of systemic AL amyloidosis, usually resulting in nephrotic-range proteinuria. Rarely, deposits predominantly or exclusively affect the intrarenal arterioles or arteries, with these vascular-limited forms following a distinct clinical course, but very little is known about these forms. Our work planned to better characterize renal vascular-limited AL amyloidosis. METHODS: By mining a French Paris hospital database, we found that this unusual phenotype accounts for approximatively 9% of renal AL amyloidosis cases. We retrospectively studied 35 patients with the renal vascular-limited variant of AL amyloidosis on kidney biopsy. RESULTS: All showed predominant or only (n = 21) intra-renal vascular deposits, of lambda isotype in 63%. At diagnosis, median urine protein/creatinine ratio was 0.5 g/g, with serum creatinine of 181 (133-216) µmol/L and estimated glomerular filtration (eGFR) rate of 36.2 (24.3-49.6) mL/min/1.73 m2. Cardiac involvement was present in 67% of cases. A serum and/or urine monoclonal gammopathy was identified in all but one patient and 31 (88%) had an abnormal free light chain ratio. Among 28 treated patients, hematological and renal response rates were 75% (including deep hematological response in 43%) and 18%, respectively. Median time from diagnosis to renal event, defined be a composite criterion composed of end-stage renal disease or >40% decrease in eGFR, was 56 months. Median overall survival was 59 months-significantly longer in patients who achieved a deep hematological response (178 vs 20 months, P = .002). CONCLUSION: Renal vascular-limited AL amyloidosis is a probably underdiagnosed disease with markedly reduced eGFR, low-grade proteinuria and severe overall prognosis. Rapid achievement of a deep hematological response is required to preserve long-term renal and patient outcomes.
引用
- Senot N, Gibier JB, Rabant M, et al. Epidemiological and clinicopathological characteristics of vascular-limited renal AL amyloidosis. Nephrol Dial Transplant. 2025. PMID: 39668632. doi:10.1093/ndt/gfae285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。